Localization of i-labelled monoclonal antibody eric1 in a subcutaneous xenograft model of neuroblastoma in scid mice

Nuclear Medicine Communications

Volumn 27, Issue 2, 2006, Pages 171-178

  Otto, Christina ^a   Jensen, Markus ^b   Dietlein, Markus ^c   Fischer, Thomas ^c   Schmidt, Matthias ^c   Tawadros, Samir ^c   Maria Börner, Sarah ^c   Alfred Weber, Sebastian ^c   Spitz, Rüdiger ^c   Bloch, Wilhelm ^c   Berthold, Frank ^c   Schicha, Harald ^c   Schomäcker, Klaus ^c  

^a Paediatric Oncology and Haematology   (Belgium)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Anti NCAM; Antibody ERIC1; Neuroblastoma; Radioimmunoscintigraphy; SCID mouse model

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; ERIC1 ANTIBODY; IODINE 131; UNCLASSIFIED DRUG;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; DISEASE MODEL; FEMALE; IMMUNOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; NEUROBLASTOMA; RADIOIMMUNOTHERAPY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; WHOLE BODY COUNTING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; IMMUNOLOCALIZATION; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; SCID MOUSE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, SCID; NEURAL CELL ADHESION MOLECULES; NEUROBLASTOMA; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 33645237745     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000194400.04820.7d     Document Type: Article

References (28)

1. Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80:2321-2332.
2. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robinson LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997; 19:428-432.
3. Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center Experience and a literature review. Cancer 2001; 91:1510-1519.
4. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59:1261-1277.
5. Raggi CC, Maggi M, Renzi D, Calabrò A, Bagnoni ML, Scaruffi P, et al. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 2000; 85:3866-3873.
6. Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 2004; 45:1172-1188.
7. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 1999; 43:336-343.
8. D2 monoclonal antibody to neuroblastoma. J Nucl Med 1987; 28:1577-1583.
9. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992; 35:199-204.
10. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxity with a chimeric anti-GD2 antibody. J Immunol 1990; 4:1382-1386.
11. Hoefnagel CA, Rutgers M, Buitenhuis CKM, Smets LA, de Kraker J, Meli M, et al. A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 2001; 28:359-368.
12. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Infants with stage 4 neuroblastoma: The impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Pädiatr 2005; 217:147-152.
13. Roy D, Ouellet S, Le HC, Ariniello P, Perreault C, Lambert J. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Natl Cancer Inst 1996; 88:1136-1145.
14. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993; 67:144-151.
15. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiotherapy Oncol 1995; 34:121-131.
16. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F. NK cell depletion diminish tumour-specific B cell responses. Immunol Lett 2004; 93:205-210.
17. Lashford L, Jones D, Pritchard J, Gordon I, Breatnach F, Kemshead JT. Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma. Natl Cancer Inst Monogr 1987; 3:53-57.
18. Goldman A, Vivian G, Gordon I, Pritchard J, Kemshead J. Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A. J Pediatr 1984; 105:252-256.
19. Jones DH, Lashford LS, Dicks-Mireaux C, Kemshead JT. Comparison of Pharmacokinetics of radiolabeled monoclonal antibody UJ13A in patients and animal models. Natl Cancer Inst Monogr 1987; 3:125-130.
20. Bourne S, Patel K, Walsh F, Popham C, Coakham H, Kemshead JT. A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm. J Neurooncol 1991; 10:111-119.
21. Jensen M, Ernestus K, Kemshead J, Klehr M, von Bergwelt-Baildon MS, Schinköthe T, et al. The bi-specific CD3×NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clin Exp Immunol 2003; 134:253-263.
22. Greenwood FC, Hunter WM, Glover JS. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89:114-123.
23. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-580.
24. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1948; 51:660-672.
25. 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 2001; 7:3186-3192.
26. Fichtner I, Lemm M, Becker M, Berthold F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs 1997; 8:174-181.
27. Fischer T, Zimmermanns B, Börner S, Pogge E, Tawadros S, Engert A, Schomäcker K. New anti-Hodgkin-radioimmunoconjugates (RIC): Consequences of variation of labelling nuclide and RIC-size to biodistribution. Nuklear Medicine 2004; 43:A132.
28. Marinelli LD. Dosage determination in the use of radioactive isotypes. J Clin Invest 1949; 28:1271-1280.